Radical surgical resection is the only curative treatment option for pancreatic cancer, but borderline resectable tumors have a high probability of incomplete exeresis. Although neoadjuvant therapy can improve the chances of complete exeresis, not all patients respond as expected.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
The number of type A BR-PDAC patients who, after receiving NAT (≥3 cycles), undergo resection.
Timeframe: From 6 weeks until the end of the observation period (December 2019) or death (whichever occurs first)
The evolution of the plasmatic levels of CA 19-9 from starting NAT until the surgical exploration.
Timeframe: Up to 16 weeks
The evolution of the degree of vascular involvement in 64-MDCT scans from starting NAT until the surgical exploration.
Timeframe: Up to 16 weeks
Overall survival
Timeframe: From starting NAT until the end of the observation period (December 2019) or death (whichever occurs first).
The evolution of the plasmatic levels of CA 19-9
Timeframe: From starting NAT until end of the observation period (December 2019) or death (whichever occurs first).
The evolution of the degree of vascular involvement in 64-MDCT scans
Timeframe: From starting NAT until end of the observation period (December 2019) or death (whichever occurs first).
Progression-Free Survival
Timeframe: From starting NAT until end of the observation period (December 2019) or disease progression (whichever occurs first).
The evolution of the plasmatic levels of CA 19-9
Timeframe: From starting NAT until end of the observation period (December 2019) or disease progression (whichever occurs first).
The evolution of the degree of vascular involvement in 64-MDCT scans
Timeframe: From starting NAT until end of the observation period (December 2019) or disease progression (whichever occurs first).